{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:10:42Z","timestamp":1762431042547},"reference-count":45,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T00:00:00Z","timestamp":1445472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA189872","CA189953","CA189954","CA189804","CA189830","CA189858","CA189808","CA189860","CA189957"],"award-info":[{"award-number":["CA189872","CA189953","CA189954","CA189804","CA189830","CA189858","CA189808","CA189860","CA189957"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA11083","CA35119"],"award-info":[{"award-number":["CA11083","CA35119"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Bortezomib is active in mantle cell lymphoma (<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>), with approval in upfront and relapsed settings. Given inevitable recurrence following induction chemoimmunotherapy, maintenance approaches are a rational strategy to improve clinical outcomes. We conducted a phase<jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>study to evaluate the safety and efficacy of six cycles of R\u2010<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>(rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) plus bortezomib (1\u00b73\u00a0mg\/m<jats:sup>2<\/jats:sup>days 1 and 4 of 21\u00a0d cycles) followed by bortezomib maintenance (1\u00b73\u00a0mg\/m<jats:sup>2<\/jats:sup>days 1, 4, 8, and 11 every 3\u00a0months for 2\u00a0years). Sixty\u2010five eligible patients were enrolled. The treatment was well tolerated and toxicities were mainly haematological. The rate of grade \u22653 peripheral neuropathy was low (5%). With a median follow\u2010up of 6\u00b78\u00a0years, 2\u2010year progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) was 62%, and 2\u2010year overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) was 85%. At 5\u00a0years,<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>was 28% and<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>was 66%.<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>International Prognostic Index scores were significantly associated with 2\u2010year<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>, but did not predict long\u2010term (\u22655\u2010year)<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>. Baseline Ki\u201067 index was significantly associated with survival. Combination R\u2010<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>with bortezomib followed by maintenance bortezomib appears to improve outcomes compared historically with R\u2010<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>alone, with prolonged remissions in a subset of patients. These results suggest that inclusion of bortezomib with induction chemotherapy and\/or maintenance is promising in<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>and warrants further exploration.<\/jats:p>","DOI":"10.1111\/bjh.13818","type":"journal-article","created":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T13:37:28Z","timestamp":1445607448000},"page":"208-218","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Phase<scp>II<\/scp>trial of R\u2010<scp>CHOP<\/scp>plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma:<scp>SWOG<\/scp>S0601"],"prefix":"10.1111","volume":"172","author":[{"given":"Brian G.","family":"Till","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center Seattle WA USA"},{"name":"University of Washington Medical Center Seattle WA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongli","family":"Li","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center Seattle WA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven H.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Center University of Rochester Rochester NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard I.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center Temple University School of Medicine Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Richard","family":"Burack","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Center University of Rochester Rochester NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Rimsza","sequence":"additional","affiliation":[{"name":"Arizona Cancer Center University of Arizona Tucson AZ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin D.","family":"Floyd","sequence":"additional","affiliation":[{"name":"Heartland NCORP\/Saint Francis Medical Center Cape Girardeau MO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco A.","family":"DaSilva","sequence":"additional","affiliation":[{"name":"Southeast Cancer Consortium\u2010Upstate NCORP\/Kingsport Hem &amp; Onc Associates Kingsport TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Dennis F.","family":"Moore","sequence":"additional","affiliation":[{"name":"Wichita NCORP\/Cancer Center of Kansas Wichita KS USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Pozdnyakova","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Chicago Hospitals Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center Seattle WA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Center University of Rochester Rochester NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,10,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559930"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.760041"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl316"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04438.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500144490"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523845"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2454"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox D.R.","year":"1972","journal-title":"Journal of the Royal Statistical Society, Series B"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_2_8_11_1","article-title":"Bortezomib\u00a0+\u00a0DA\u2010EPOCH\u2010R induction therapy followed by maintenance bortezomib versus observation in newly diagnosed mantle cell lymphoma","volume":"120","author":"Dunleavy K.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-314708"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25509"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07775.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.483302"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.252462599"},{"key":"e_1_2_8_22_1","article-title":"Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA\u2010C Containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the european mantle cell lymphoma network (MCL net)","volume":"116","author":"Hermine O.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2466"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1288"},{"key":"e_1_2_8_26_1","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-009-0036-x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_2_8_30_1","article-title":"Rituximab maintenance versus wait and watch after four courses of R\u2010DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: first interim analysis of the phase III prospective lyma trial, a lysa study","volume":"124","author":"Le Gouill S.","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2049-5"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1173"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12854"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400580"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.88"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0287"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.021113"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75247"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6789"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05716.x"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404959"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13818","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T23:20:02Z","timestamp":1718148002000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,22]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1111\/bjh.13818"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13818","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,22]]},"assertion":[{"value":"2015-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-09-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}